Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 420

1.

Rapid, early and sustained virological responses in a cohort of Irish patients treated with pegylated interferon and ribavirin for chronic hepatitis C virus infection.

Sarwar S, Ryan EJ, Iqbal M, McCormick PA, O'Farrelly C, Hegarty J.

Ir J Med Sci. 2012 Mar;181(1):53-8. doi: 10.1007/s11845-011-0775-4. Epub 2011 Oct 29.

PMID:
22038749
[PubMed - indexed for MEDLINE]
2.
3.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
[PubMed - indexed for MEDLINE]
4.

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.

Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.

Biomed Pharmacother. 2011 Jul;65(4):303-6. doi: 10.1016/j.biopha.2011.03.004. Epub 2011 May 30.

PMID:
21723079
[PubMed - indexed for MEDLINE]
5.

Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.

Namikawa M, Kakizaki S, Yata Y, Yamazaki Y, Horiguchi N, Sato K, Takagi H, Mori M.

J Gastroenterol Hepatol. 2012 Jan;27(1):69-75. doi: 10.1111/j.1440-1746.2011.06802.x.

PMID:
21649727
[PubMed - indexed for MEDLINE]
6.

Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.

Zhou YQ, Wang XH, Hong GH, Zhu Y, Zhang XQ, Hu YJ, Mao Q.

J Viral Hepat. 2011 Aug;18(8):595-600. doi: 10.1111/j.1365-2893.2010.01373.x. Epub 2010 Nov 24.

PMID:
21105968
[PubMed - indexed for MEDLINE]
7.

The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.

Napoli N, Giannelli G, Antonaci A, Antonaci S.

J Viral Hepat. 2008 Apr;15(4):300-4. doi: 10.1111/j.1365-2893.2007.00944.x.

PMID:
18307592
[PubMed - indexed for MEDLINE]
8.

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.

Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S.

J Hepatol. 2011 Jul;55(1):69-75. doi: 10.1016/j.jhep.2010.10.032. Epub 2010 Nov 23.

PMID:
21145856
[PubMed - indexed for MEDLINE]
9.

Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.

Aziz H, Raza A, Waheed Y, Gill U, Gill ML.

Int J Infect Dis. 2012 Aug;16(8):e597-602. doi: 10.1016/j.ijid.2012.03.012. Epub 2012 Jun 1.

PMID:
22658873
[PubMed - indexed for MEDLINE]
Free Article
10.

Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.

Huang CF, Yang JF, Huang JF, Dai CY, Chiu CF, Hou NJ, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL, Yu ML.

J Gastroenterol Hepatol. 2010 Apr;25(4):758-65. doi: 10.1111/j.1440-1746.2009.06148.x.

PMID:
20492331
[PubMed - indexed for MEDLINE]
11.

Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.

Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.

AIDS. 2008 Jan 2;22(1):15-21.

PMID:
18090387
[PubMed - indexed for MEDLINE]
12.

A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.

Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K.

J Hepatol. 2012 May;56(5):1012-8. doi: 10.1016/j.jhep.2011.12.020. Epub 2012 Jan 17.

PMID:
22266603
[PubMed - indexed for MEDLINE]
13.

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.

Mach TH, Cieśla A, Warunek W, Janas-Skulina U, Cibor D, Owczarek D, Ciećko-Michalska I.

Pol Arch Med Wewn. 2011 Dec;121(12):434-9.

PMID:
22157768
[PubMed - indexed for MEDLINE]
Free Article
14.

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.

Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.

Liver Transpl. 2008 Jan;14(1):53-8.

PMID:
18161839
[PubMed - indexed for MEDLINE]
Free Article
15.

[Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].

Li MH, Chen LJ, Qiu GH, Lu Y, Xie Y, Xu DZ.

Zhonghua Gan Zang Bing Za Zhi. 2009 Jul;17(7):497-500. Chinese.

PMID:
19912682
[PubMed - indexed for MEDLINE]
16.

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.

PMID:
18679072
[PubMed - indexed for MEDLINE]
17.

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2012;17(3):477-84. doi: 10.3851/IMP2026. Epub 2011 Dec 20.

PMID:
22301466
[PubMed - indexed for MEDLINE]
18.

The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.

Dogan UB, Atabay A, Akin MS, Yalaki S.

Eur J Gastroenterol Hepatol. 2013 Sep;25(9):1082-5. doi: 10.1097/MEG.0b013e32836076d1.

PMID:
23524524
[PubMed - indexed for MEDLINE]
19.

Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.

Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK, Das A, Chawla YK.

Dig Dis Sci. 2011 Aug;56(8):2449-55. doi: 10.1007/s10620-011-1770-3. Epub 2011 Jun 25.

PMID:
21706207
[PubMed - indexed for MEDLINE]
20.

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; ITAHEC Study Group.

Aliment Pharmacol Ther. 2011 May;33(10):1162-72. doi: 10.1111/j.1365-2036.2011.04635.x. Epub 2011 Mar 28.

PMID:
21443535
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk